{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:18Z","timestamp":1792842258619,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejphar.2023.175936","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T15:09:22Z","timestamp":1690988962000},"page":"175936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo"],"prefix":"10.1016","volume":"956","author":[{"given":"Moritaka","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175936_bib1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3762\/bjoc.8.158","article-title":"A novel asymmetric synthesis of cinacalcet hydrochloride","volume":"8","author":"Arava","year":"2012","journal-title":"Beilstein J. Org. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2023.175936_bib32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI117890","article-title":"Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia","volume":"95","author":"Arnold","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175936_bib2","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.3748\/wjg.v12.i33.5363","article-title":"In vitro and in vivo effects of ferulic acid on gastrointestinal motility: inhibition of cisplatin-induced delay in gastric emptying in rats","volume":"12","author":"Badary","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.175936_bib3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: first global approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2023.175936_bib4","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175936_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000325454","article-title":"FARO Study Group, Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality","volume":"32","author":"Brancaccio","year":"2011","journal-title":"Blood Purif."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175936_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.175936_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/ndt\/gfp616","article-title":"Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate","volume":"25","author":"Canalejo","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175936_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.beem.2013.05.010","article-title":"Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways","volume":"27","author":"Conigrave","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2023.175936_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2023.175936_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/IJNRD.S128252","article-title":"Managing hyperparathyroidism in hemodialysis: role of etelcalcetide","volume":"11","author":"Eidman","year":"2018","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"key":"10.1016\/j.ejphar.2023.175936_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2369-15-69","article-title":"Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5\/6 nephrectomy and adenine models","volume":"15","author":"Ferrari","year":"2014","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175936_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175936_bib30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175936_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4009\/jsdt.43.309","article-title":"The mechanism of upper-gastrointestinal complication after taking cinacalcet hydrochloride","volume":"43","author":"Fukumoto","year":"2010","journal-title":"J. Jpn. Soc. Dial. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175936_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.ejphar.2023.175936_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2018.10.021","article-title":"Pharmacology of Parsabiv \u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients","volume":"842","author":"Harada","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejphar.2023.175936_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ph15080952","article-title":"Role of calcimimetics in treating bone and mineral disorders related to chronic kidney disease","volume":"15","author":"Hou","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"13","key":"10.1016\/j.ejphar.2023.175936_bib15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-021-01578-y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2023.175936_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejphar.2023.175936_bib31","first-page":"1598","article-title":"Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism","volume":"81","author":"Kifor","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175936_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s40268-022-00385-4","article-title":"First-in-human phase I study of the novel injectable calcimimetic agent upacicalcet in healthy adult Japanese participants","author":"Koiwa","year":"2022","journal-title":"Drugs R"},{"issue":"2","key":"10.1016\/j.ejphar.2023.175936_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000190282","article-title":"Carbohydrate diet prolongs survival of rats with acute uremia after bilateral nephrectomy","volume":"77","author":"Levine","year":"1997","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.ejphar.2023.175936_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and calcilytic drugs: feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.ejphar.2023.175936_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175936_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2023.175936_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175936_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/nu5010302","article-title":"Calcium nutrition and extracellular calcium sensing: relevance for the pathogenesis of osteoporosis, cancer and cardiovascular diseases","volume":"5","author":"Peterlik","year":"2013","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.ejphar.2023.175936_bib34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1046\/j.1523-1755.2001.00027.x","article-title":"Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor","volume":"60","author":"Ritter","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2023.175936_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116613","article-title":"Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model","volume":"167","author":"Sato","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2023.175936_bib25","series-title":"Hypocalcemia: Diagnosis and Treatment","author":"Schafer","year":"2016"},{"key":"10.1016\/j.ejphar.2023.175936_bib26","series-title":"Electrolytes","author":"Shrimanker","year":"2021"},{"issue":"6","key":"10.1016\/j.ejphar.2023.175936_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000299794","article-title":"Vascular calcification in animal models of CKD: a review","volume":"31","author":"Shobeiri","year":"2010","journal-title":"Am. J. Nephrol."},{"issue":"2","key":"10.1016\/j.ejphar.2023.175936_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300448X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300448X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:18:09Z","timestamp":1728407889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992300448X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"alternative-id":["S001429992300448X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175936","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175936"}}